Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021Business Wire • 02/25/21
Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?Zacks Investment Research • 02/24/21
Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to CatalentBusiness Wire • 02/11/21
Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into “At The Market” Offering AgreementBusiness Wire • 01/13/21
Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care ConferenceBusiness Wire • 01/12/21
Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual ConferenceBusiness Wire • 01/11/21
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/04/20
Acorda Therapeutics (ACOR) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/03/20
Acorda Third Quarter 2020 Update: Webcast/Conference Call Scheduled for November 3, 2020Business Wire • 10/27/20
Acorda Therapeutics (ACOR) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/26/20
Are Options Traders Betting on a Big Move in Acorda Therapeutics (ACOR) Stock?Zacks Investment Research • 09/29/20
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
Acorda Second Quarter 2020 Update: Webcast/Conference Call Scheduled for August 4, 2020Business Wire • 07/28/20
Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?Zacks Investment Research • 06/09/20
Acorda (ACOR) Down 11.8% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 06/04/20